Survodutide
Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim. The glucagon component adds liver fat reduction, promising for fatty liver disease alongside obesity.
Key Facts
- ClassificationPeptide — Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim.
- Primary BenefitsFat Loss (9/10) · Gut Health (5/10) · Longevity (4/10)
- AdministrationInjection
- Typical DoseStart at 0.6 mg per week and gradually increase. Up to 4.8 mg/week was tested for weight loss; 6.0 mg was tested in liver disease (MASH) trials. Meant for long-term use.
- Evidence StrengthEmerging — 20 peer-reviewed studies referenced · Community sentiment 5/10
- Stacks Well With5-Amino-1MQ, MOTS-c, BPC-157
- Legal StatusPhase 2/3 Clinical Trials · not prescribable in US · WADA prohibited
Quick Facts
- From price
- $100
- Type
- peptide
- Administration
- Injection
- Evidence
- emerging
- Studies referenced
- 20
- Community sentiment
- 5/10
- Stacks with
- 3 peptides
- Regulatory
- Phase 2/3 Clinical Trials
Top benefits
Dosing
Start at 0.6 mg per week and gradually increase. Up to 4.8 mg/week was tested for weight loss; 6.0 mg was tested in liver disease (MASH) trials. Meant for long-term use.
Benefit Profile
| Vendor | Variant | Price | |
|---|---|---|---|
| Limitless Biotech | 3mg | $109.99 | Code: PSTACK10Buy |
| Skye Peptides | 3mg | $99.99BEST |
Stacks Well With
5-Amino-1MQ
Small molecule blocking NNMT, an enzyme that slows metabolism. Increases NAD+ production and energy expenditure. Promotes fat loss and may fix metabolic issues.
MOTS-c
Mitochondrial DNA-encoded peptide that activates AMPK, improving insulin sensitivity, fat burning, and mimicking exercise at the cellular level. Stacks well with SS-31 and NAD+.
BPC-157
A healing compound from human gastric juice. The most extensively studied repair peptide in animal models, with strong preclinical data for tissue repair, gut restoration, and anti-inflammatory effects. Human clinical data remains limited.
Related 🔥 Fat Loss Peptides
Other peptides strong in fat loss
GLP-1 drug (Ozempic/Wegovy) that suppresses appetite and burns fat.
Tirzepatide10/10Dual GLP-1/GIP drug (Mounjaro/Zepbound). Strongest weight loss peptide available.
Retatrutide10/10Triple-action weight loss drug hitting GLP-1, GIP, and glucagon receptors.
CagriSema10/10Next-gen dual semaglutide + amylin analog with strongest weight loss data.
Mazdutide9/10Dual GLP-1/glucagon receptor drug with strong weight loss results.
Orforglipron9/10First oral non-peptide GLP-1 agonist in late-stage trials.